Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2- Advanced Breast Cancer.

Curr Oncol · 2025 · PMC11764237 · PMID 39851968

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.173not close (p > 0.1)

showed a trendno p-value reported

For the OS, a PR-positive status showed a trend toward reduced mortality risk compared with the PR-negative patients (HR, 0.61; 95% CI, 0.30–1.24), though this did not reach statistical significance ( p = 0.173).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.